^
Association details:
Biomarker:PIK3CA amplification
Cancer:Chordoma
Drug:everolimus (mTOR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification.

Published date:
05/19/2021
Excerpt:
Table summarizes matched therapies in responders....Chordoma...PIK3CA amplification...Everolimus – SD, 6 mo.
DOI:
10.1200/JCO.2021.39.15_suppl.11538